Even when caught early enough to be surgically curable, a substantial portion of patients will see their cancer return.
In Brazil, the health regulator Anvisa has expanded approval for tislelizumab — an immunotherapy already familiar to oncology — to encompass the full surgical arc of resectable non-small cell lung cancer, from pre-operative preparation to post-operative vigilance. The decision reflects a deepening conviction in modern medicine that the immune system, properly awakened, may accomplish what surgery and chemotherapy alone cannot: the permanent silencing of a disease prone to quiet return. For the many patients whose early-stage lung cancer carries the shadow of recurrence, this approval represents not a cure promised, but a better-armed fight.
- Non-small cell lung cancer, the most common form of the disease globally, kills with particular cruelty — even surgically removed tumors return in a substantial share of patients, making recurrence prevention one of oncology's most urgent unsolved problems.
- Tislelizumab's expanded approval breaks new ground in Brazil by authorizing its use both before and after surgery, a dual-phase strategy that no prior regulatory clearance for this drug had covered in this setting.
- The treatment protocol pairs chemotherapy with immunotherapy before the surgeon operates — potentially shrinking tumors and priming the immune system — then continues immunotherapy alone afterward to hunt down any microscopic disease that escaped the scalpel.
- Anvisa's decision signals regulatory confidence that the benefit-to-risk balance favors high-risk patients, though the real-world test will be identifying who gains most and managing the side effects immunotherapy can carry.
- The approval joins a broader oncological tide: immunotherapy is steadily displacing chemotherapy-only standards across cancer types, and similar combination approvals in other malignancies are likely to follow.
Brazil's Anvisa has cleared an expanded use for tislelizumab — marketed as Tevimbra® — authorizing it for patients with early-stage, surgically removable non-small cell lung cancer. The drug, a monoclonal antibody that blocks immune checkpoints, will now be administered alongside platinum-based chemotherapy before surgery, then continued alone afterward as a maintenance strategy against recurrence.
The target is a familiar and frustrating problem: non-small cell lung cancer accounts for the majority of lung tumors worldwide and, even when caught early enough for surgery, returns in a troubling proportion of patients. For decades, chemotherapy after surgery was the standard response. Immunotherapy is now changing that equation — not by replacing the surgeon's work, but by preparing the immune system before the operation and keeping it vigilant long after.
The mechanism carries a certain elegance. Chemotherapy can damage tumor cells in ways that make them more recognizable to immune defenses, while tislelizumab removes the molecular signals cancer uses to hide from those defenses. Together, they aim to close the gap between a successful operation and a lasting remission.
This approval is the first time tislelizumab has been authorized in Brazil for this neoadjuvant and adjuvant setting — before and after surgery — in lung cancer. It adds another option to a treatment landscape that has been quietly transformed over the past decade, as immunotherapy moved from last resort to frontline strategy for high-risk patients. The clinical work ahead will determine which patients benefit most, but the regulatory decision reflects a considered judgment that for those with the most to lose to recurrence, the combination is worth the risk.
Brazil's health regulator has cleared a new use for tislelizumab, an immunotherapy drug already in use against other cancers, to treat patients with early-stage lung tumors that can still be surgically removed. The drug, sold domestically under the brand name Tevimbra®, will now be given in combination with platinum-based chemotherapy before surgery, then continued afterward as a maintenance treatment to keep the disease from returning.
The approval targets a specific and common problem in oncology: non-small cell lung cancer, which accounts for the majority of all lung tumors worldwide, carries high mortality rates, and has a stubborn tendency to recur even after successful surgical removal. Patients deemed at high risk for this recurrence—those whose tumors have characteristics suggesting aggressive behavior or spread—are the focus of this expanded indication. The strategy reflects a broader shift in cancer treatment toward harnessing the body's own immune system to recognize and attack tumor cells, rather than relying solely on chemotherapy's blunt force.
What makes this approval significant is its timing and scope. Tislelizumab already had regulatory approval for other cancer indications in Brazil, but this marks the first time it has been authorized for use in the neoadjuvant and adjuvant setting—that is, before and after surgery—in resectable lung cancer. The protocol is straightforward in concept: give chemotherapy and immunotherapy together before the surgeon operates, remove the tumor, then continue the immunotherapy alone to mop up any microscopic disease that might have escaped.
Non-small cell lung cancer is not rare. It is the most frequent form of lung cancer globally, and even when caught early enough to be surgically curable, a substantial portion of patients will see their cancer return within months or years. This recurrence is what drives the search for better adjuvant strategies—treatments given after primary therapy to reduce the risk of relapse. For decades, chemotherapy alone was the standard. But immunotherapies, which work by releasing the brakes on the immune system so it can recognize cancer cells as foreign invaders, have begun to change that calculus.
The Anvisa decision reflects data suggesting that adding immunotherapy to the treatment sequence improves disease control and extends the time patients remain cancer-free. The mechanism is elegant: chemotherapy can damage tumor cells in ways that make them more visible to the immune system, while the immunotherapy drug itself—tislelizumab is a monoclonal antibody that blocks a specific immune checkpoint—removes the signals that allow cancer cells to hide from immune surveillance.
In recent years, immunotherapy has transformed the landscape of lung cancer treatment, particularly in advanced disease and in high-risk early-stage cases. What was once a death sentence with limited options has become a disease with multiple therapeutic pathways, each tailored to the patient's tumor characteristics and risk profile. This approval adds another tool to that growing arsenal, giving oncologists and their patients another way to fight back against a disease that kills hundreds of thousands annually.
The real test will come in the clinic, where doctors must identify which patients truly benefit most from this combination approach and manage the side effects that can accompany immunotherapy. But the regulatory green light signals confidence that the benefit outweighs the risk for the population it targets—high-risk patients with resectable non-small cell lung cancer who have the most to gain from aggressive, multimodal treatment.
Citações Notáveis
The strategy aims to reduce tumor progression and increase the chances of prolonged disease control.— Anvisa (Brazilian health regulator)
A Conversa do Hearth Outra perspectiva sobre a história
Why does a drug that already exists need a new approval? Isn't it already approved in Brazil?
It was approved for other cancers, yes. But regulatory approval is specific to each indication—each disease and each treatment sequence. Using it before and after surgery for lung cancer is a different clinical question than using it for, say, gastric cancer. The data had to show it works in this specific setting.
So the drug itself is proven safe. This is about proving it works for this particular cancer at this particular stage.
Exactly. And it's not just about safety. It's about whether adding it to chemotherapy before surgery, then continuing it after, actually reduces the chance the cancer comes back. That's what the trials had to demonstrate.
How many patients are we talking about here? Is this a small group or a large population?
Non-small cell lung cancer is the most common type of lung cancer globally. A significant portion of those patients have tumors that can be surgically removed. So the potential population is substantial—thousands of patients in Brazil alone who might benefit.
What happens to patients who don't get this drug? Do they just get chemotherapy and surgery?
Traditionally, yes. Surgery to remove the tumor, maybe chemotherapy before or after, and then surveillance. But many of those patients will see their cancer return. This approval gives doctors another option for the ones at highest risk of recurrence.
Is this the only immunotherapy approved for this use in Brazil?
No. Other immunotherapies have been approved for similar indications. But each drug works slightly differently, and each approval expands the toolkit. More options mean doctors can match treatments to individual patient characteristics.
What's the downside? Immunotherapy can have serious side effects.
That's the trade-off. Immunotherapies can cause inflammation in various organs—the lungs, heart, liver, colon. Patients need careful monitoring. But for someone at high risk of cancer recurrence, the benefit of reducing that risk often outweighs the risk of manageable side effects.